HC Wainwright Reaffirms “Buy” Rating for Talphera (NASDAQ:TLPH)

HC Wainwright reiterated their buy rating on shares of Talphera (NASDAQ:TLPH) in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the stock. HC Wainwright also issued estimates for Talphera’s Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.29) EPS and Q4 2025 earnings at ($0.32) EPS.

Separately, Maxim Group assumed coverage on Talphera in a research report on Monday, May 6th. They set a buy rating and a $3.00 price target on the stock.

Talphera Trading Up 2.6 %

Talphera stock opened at $0.89 on Friday. The business’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $1.03. Talphera has a 12 month low of $0.43 and a 12 month high of $1.61. The company has a market cap of $15.17 million, a price-to-earnings ratio of -1.00 and a beta of 0.33.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Talphera stock. Turtle Creek Wealth Advisors LLC purchased a new position in Talphera, Inc. (NASDAQ:TLPH) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 71,500 shares of the company’s stock, valued at approximately $64,000. Turtle Creek Wealth Advisors LLC owned 0.42% of Talphera at the end of the most recent reporting period. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.